Navigation Links
New Data for XL880, XL647 and XL184 to Be Presented at AACR-NCI-EORTC
Date:10/8/2007

- A Total of 13 Abstracts for Eight Compounds Being Presented - - Investor Briefing to be Webcast on October 24, 2007 at 6:00 PM PDT -

SOUTH SAN FRANCISCO, Calif., Oct. 8 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) today announced that data from ongoing phase 2 trials of XL880 and XL647 in papillary renal cell carcinoma and non-small cell lung cancer, respectively, will be presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, which will be held October 22-26, 2007 in San Francisco. In addition, phase 1 data for XL184, which inhibits MET, VEGFR2 and RET, will also be presented. In total, 13 abstracts for eight compounds have been accepted for poster presentation at the conference, reporting data from clinical trials or preclinical studies of XL880, XL647, XL184, XL147, XL765, XL820, XL844 and XL518.

"With 13 abstracts covering eight clinical-stage compounds, the 2007 AACR-NCI-EORTC meeting is an important opportunity to highlight the breadth and depth of our pipeline," said George A. Scangos, Ph.D., president and chief executive officer of Exelixis. "Critical to our goal of building a world-class oncology franchise is the rapid advancement of the 14 compounds currently in the clinic and the continued ability to advance additional compounds into development. We believe our strong presence at this meeting is evidence of our productivity. Three of the phase 1 compounds that will be discussed were preclinical compounds at this time last year and we will present phase 2 data from trials that were initiated less than 18 months ago."

Exelixis will hold a briefing for investors and analysts on Wednesday, October 24, 2007, from 6:00-8:00 p
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
4. Clinical Data From Nymox BPH Drug To Be Presented at American Urological Association Meeting
5. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
6. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
7. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
8. MEDIA ADVISORY: Subsets of Landmark Diabetes Trials Investigating MacroVascular Outcomes Presented at the American Diabetes Association 67th Scientific Sessions
9. Nymox Announces NX-1207 Data to Be Presented at Upcoming U.S. Urology Meetings
10. ConjuChem Biotechnologies Reports PC-DAC:Exendin-4 Albumin Conjugate Data Presented at American Diabetes Association Annual Meeting
11. New Data Presented on Micardis (Telmisartan) Tablets in Hypertensive Patients With Type 2 Diabetes

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)...f., Nov. 25 Abaxis, Inc....facturing point-of-care blood analysis systems, an...ief executive officer, will present at the 21st An...sday, December 2, 2009 at 2:00 p.m. ET. The confer...New York City. ,, About Abaxis ,, Abaxis ...
(Date:11/25/2009)... Nov. 25 Reportlinker.com announce...n its catalogue: ,, Pain Management - Global ...20/Pain-Management---Global-Trends.html ,, Wid...f pain management clinics, and the advent of new d...in management market. Healthcare reforms and reimb...
(Date:11/24/2009)...DA, Md., Nov. 24 /PRNewswire-Asia/ -- Chindex Inte...ading independent American provider of Western,hea...blic of China, today,announced that the Company wi..." Health Care Conference, to be held December 1 - ...Management is currently scheduled to present at 11...
Breaking Medicine Technology:Reportlinker Adds Pain Management - Global Trends 2Reportlinker Adds Pain Management - Global Trends 3Reportlinker Adds Pain Management - Global Trends 4Reportlinker Adds Pain Management - Global Trends 5Reportlinker Adds Pain Management - Global Trends 6Chindex International to Present at Piper Jaffray Health Care Conference 2Genetic testing may be valuable in treating colorectal cancer 52793 1Genetic testing may be valuable in treating colorectal cancer 52793 2Nanophysics 3A Serving up Buckyballs on a silver platter 9367 1Researchers capture bacterial infection on film 9362 1Researchers capture bacterial infection on film 9362 2
...ulticenter,trial monitoring CellCept(R) (mycopheno...bitors (CNIs) in renal transplantation was present.... The study results showed that a,reduced level of... is not,inferior to that of a fixed dose of CellCe...biopsy-proven acute rejection (BPAR) and other end...
...tics, Inc. (Nasdaq: TPTX ) today announced it has...sic effect of NGX426, the oral prodrug,of its lead...double-blind, placebo-controlled Phase I trial wil...in the United States. The,trial is designed to eva...o,assess the time of onset, magnitude and duration...
Other Medicine Technology:CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI 2CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI 3CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI 4CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI 5CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI 6TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel 2TorreyPines Therapeutics Initiates Clinical Trial to Evaluate Analgesic Effect of Oral Prodrug of Tezampanel 3
(Date:11/27/2009)... Voyant Health™ annou...higan) has licensed its TraumaCad Enterprise ortho... workflow solution. , (PR...ounced today that Spectrum Health (Grand Rapids, M...hopedic templating solution and its TraumaCad Exte...
(Date:11/27/2009)... Three new interactive anat...lliams & Wilkins expand health sciences learni... Durham, NC (Vocus) November 27... & Wilkins (LWW), a division of Wolters Kluwer... new anatomy education apps on the App Store. Clem...
(Date:11/26/2009)...In the next 25 years, the number of Americans livi...om 23.7 million in 2009 to 44.1 million in 2034. O...ost triple, rising from $113 billion to $336 billi...sity, researchers based at the University of Chica.... , The number of those with diabetes covered by...
(Date:11/26/2009)...ns get a bigger thrill when on an emotional roller...26 (HealthDay News) -- Call it the fear factor mee...sts that spectators -- especially those who root f...tion if it,s a closely contested match and victory...n despair. , Chew on that this Thanksgiving wee...
(Date:11/26/2009)... Research Triangle Dental (...ral North Carolina, today announced the expansion ...d LUMINEER Dentist, Dr. Doug Macmillan. , ... Triangle Dental is pleased to announce that Dr. D... recently completed an additional advanced trainin...
Breaking Medicine News(10 mins):Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 2Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 3Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 4Health News:Clemente's Anatomy, Rohen's Photographic Anatomy, and Moore's Clinical Anatomy Customizable Apps Now Available on App Store 5Health News:Diabetes cases to double and costs to triple by 2034 2Health News:Diabetes cases to double and costs to triple by 2034 3Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dr. Douglas Macmillan Now Providing LUMINEERS at Research Triangle Dental 2
...cent of Parents Aware of the CDC,s Flu Vaccination...ns to Join Education Effort , , NEW YORK, Feb. 4 ...Home with the flu," when their friends are all out...thor, Dr. Harley Rotbart, and The Clorox Company t...
...h., Feb. 4 Cardiac Science,(Nasdaq: CSCX ), a g...itation,rehabilitation, and informatics products, ...n and engineering services from Colorado-based Syn...10LOGO ) , "We expect considerable savings and...
...ehensive survey of global spending on neglected di... , finds that just over $US 2.5 billion was invest...seasesHIV/AIDS, TB, and malariareceiving nearly 80...nificantly underfunded. , Researchers from The ...
... Friday, February 6th, local dentists will... (PRWEB) February 4, 2009 -- Friday, ...ildren a new smile! The opportunity comes at a pe...n the nation, tooth decay. This year, many of the...
... Reid Supply Company,s President, John Car...d improved company web site, as well as the releas...s catalog. Both ReidSupply.com and the catalog are...pply focuses on enhancing the Customer experience ...
...3 ETHEX Corporation, a subsidiary of KV Pharmaceu...tary nationwide recall of the products identified ...a wholesale level. The Company is taking this act...nufacturing Practice (cGMP). , , Patients who ...
Other Medicine News:Health News:American Idol Former Finalist, Brooke White, Helps Teens Cast Flu Prevention Vote 2Health News:American Idol Former Finalist, Brooke White, Helps Teens Cast Flu Prevention Vote 3Health News:American Idol Former Finalist, Brooke White, Helps Teens Cast Flu Prevention Vote 4Health News:Cardiac Science Increases R&D Capacity With 3-year Syncroness Agreement 2Health News:Cardiac Science Increases R&D Capacity With 3-year Syncroness Agreement 3Health News:How much is the world spending on neglected disease research and development? 2Health News:A New Smile: During Tough Economic Conditions Hundreds of Kentucky Children Receive Free Dental Care 2Health News:A New Smile: During Tough Economic Conditions Hundreds of Kentucky Children Receive Free Dental Care 3Health News:New Enhanced Web Site and Catalog from Reid Supply 2Health News:New Enhanced Web Site and Catalog from Reid Supply 3Health News:ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 2Health News:ETHEX Corporation Issues Voluntary Nationwide Recall of Prescription Prenatal and Iron Supplements to Wholesale Level 3
LabPak POL Plus Laboratory Information System
...cuff for opening the drape helps ensure a sterile ...s side construction prevents x-ray cassettes from ...sette to be exposed to the sterile field. , ,Adhe... flexibility of utilizing either small or large x-...
...dinal Health will change the way you think about d...udgets and reduced reimbursements mean costs must ...ificing the quality of care or jeopardizing patien...he perspective of total value and long-term implic...
...ration with wide adhesive area. The drape has aggr...due. Aggressive adhesive with no residue.,It's mad...ilm and a split poly liner for ease of application...ilable sterile in a box of 10 or non-sterile in a ...
Medicine Products: